Naldemedine Tosylate Patent Expiration
Naldemedine Tosylate is Used for treating opioid-induced constipation. It was first introduced by Biodelivery Sciences International Inc
Naldemedine Tosylate Patents
Given below is the list of patents protecting Naldemedine Tosylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Symproic | US10952968 | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives | May 13, 2033 | Bdsi |
| Symproic | US9108975 | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same | Nov 11, 2031 | Bdsi |
| Symproic | US8084460 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | Jan 11, 2028 | Bdsi |
| Symproic | USRE46365 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | Jan 11, 2028 | Bdsi |
| Symproic | US8536192 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | Oct 05, 2026 | Bdsi |
| Symproic | USRE46375 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | Oct 05, 2026 | Bdsi |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Naldemedine Tosylate's patents.
Latest Legal Activities on Naldemedine Tosylate's Patents
Given below is the list recent legal activities going on the following patents of Naldemedine Tosylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 Feb, 2023 | US9108975 |
| Patent Issue Date Used in PTA Calculation Critical | 23 Mar, 2021 | US10952968 |
| Recordation of Patent Grant Mailed Critical | 23 Mar, 2021 | US10952968 |
| Email Notification Critical | 05 Mar, 2021 | US10952968 |
| Issue Notification Mailed Critical | 03 Mar, 2021 | US10952968 |
| Email Notification Critical | 18 Feb, 2021 | US10952968 |
| Mail Response to 312 Amendment (PTO-271) Critical | 18 Feb, 2021 | US10952968 |
| Printer Rush- No mailing | 18 Feb, 2021 | US10952968 |
| Dispatch to FDC | 17 Feb, 2021 | US10952968 |
| Response to Amendment under Rule 312 Critical | 08 Feb, 2021 | US10952968 |
Naldemedine Tosylate's Family Patents
